Metronidazole 2% Gel Versus Clindamycin 1% Gel for Moderate Acne Vulgaris
Starting soon · Phase 4
Conditions studied: Acne Vulgaris
In brief
Acne vulgaris is a common inflammatory skin disorder. This randomized controlled trial (RCT) will compare the efficacy and safety of 2% metronidazole gel versus 1% clindamycin gel in adults with moderate acne vulgaris at Jinnah Postgraduate Medical Centre (JPMC), Karachi. Sixty eligible participants (18-35 years) will be enrolled using consecutive sampling and randomized in a 1:1 ratio using blocked randomization. Participants will apply the assigned gel as a thin layer twice daily for 12 weeks. Acne severity will be assessed using the Modified Global Acne Grading System (mGAGS) at baseline and at weeks 4, 8, and 12. The primary outcome is the proportion of participants achieving at least a 50% reduction from baseline in total mGAGS score at week 12. Local adverse effects (e.g., erythema, itching, irritation) will be recorded at each follow-up visit.
Key facts
- Study ID
- NCT07392047
- Run by
- Jinnah Postgraduate Medical Centre
- People needed
- 60
- Starts
- 2026-02-01
- Expected to finish
- 2026-08-01
- Last updated by the study team
- 2026-02-06
Who can join
Age: 18 and older, up to 35. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Adults aged 18-35 years of either sex.
- Clinical diagnosis of moderate acne vulgaris, defined as a Modified Global Acne Grading System (mGAGS) score of 45-80.
- Not currently using any other anti-acne treatment (topical or systemic).
You may not qualify if…
- Pregnant or lactating women.
- Severe acne vulgaris, defined as an mGAGS score >80.
- Known hypersensitivity/allergy to metronidazole or clindamycin (or any component of the study gels).
- Any other dermatologic condition affecting the face that may interfere with assessment of acne severity or treatment response.
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.